Sarina Tanimoto Sells 100,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $9.28, for a total transaction of $928,000.00. Following the completion of the transaction, the insider now directly owns 1,647,447 shares of the company’s stock, valued at approximately $15,288,308.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Sarina Tanimoto also recently made the following trade(s):

• On Friday, March 22nd, Sarina Tanimoto sold 2,343 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.02, for a total transaction of $21,133.86.
• On Thursday, March 14th, Sarina Tanimoto sold 444 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.00, for a total transaction of $3,996.00.
• On Wednesday, February 28th, Sarina Tanimoto sold 98,778 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.02, for a total transaction of $890,977.56.
• On Monday, February 26th, Sarina Tanimoto sold 700 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.01, for a total transaction of $6,307.00.

ARS Pharmaceuticals Stock Down 6.8 %

Shares of NASDAQ SPRY opened at $8.44 on Friday. ARS Pharmaceuticals, Inc. has a fifty-two week low of $2.55 and a fifty-two week high of $11.27. The firm’s 50-day simple moving average is $8.73 and its 200 day simple moving average is $6.25. The stock has a market cap of $814.48 million, a P/E ratio of -14.81 and a beta of 0.83.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. On average, sell-side analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of SPRY. Geode Capital Management LLC bought a new stake in shares of ARS Pharmaceuticals during the first quarter valued at about $2,627,000. Squarepoint Ops LLC bought a new stake in ARS Pharmaceuticals in the first quarter worth about $84,000. State Street Corp raised its position in ARS Pharmaceuticals by 50.4% in the first quarter. State Street Corp now owns 129,191 shares of the company’s stock worth $841,000 after acquiring an additional 43,300 shares in the last quarter. Jane Street Group LLC bought a new stake in ARS Pharmaceuticals in the first quarter worth about $895,000. Finally, Ameriprise Financial Inc. bought a new stake in ARS Pharmaceuticals in the first quarter worth about $1,825,000. 68.16% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Leerink Partnrs raised shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 5th. SVB Leerink raised shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $6.00 to $18.00 in a report on Tuesday, March 5th. Wedbush reissued an “outperform” rating and set a $19.00 price target on shares of ARS Pharmaceuticals in a report on Monday, March 11th. Finally, William Blair raised shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 20th.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.